DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Federated Hermes Inc.

Federated Hermes Inc. decreased its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 8.4% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,145,706 shares of the medical device company’s stock after selling 197,117 shares during the quarter. Federated Hermes Inc. owned about 0.56% of DexCom worth $266,261,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. raised its position in shares of DexCom by 31.9% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 270,999 shares of the medical device company’s stock worth $138,643,000 after buying an additional 65,516 shares during the period. Healthcare of Ontario Pension Plan Trust Fund raised its position in shares of DexCom by 3,596.7% in the 1st quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,109 shares of the medical device company’s stock worth $567,000 after buying an additional 1,079 shares during the period. West Family Investments Inc. purchased a new position in shares of DexCom in the 1st quarter worth $209,000. Ergoteles LLC raised its position in shares of DexCom by 60.6% in the 1st quarter. Ergoteles LLC now owns 1,681 shares of the medical device company’s stock worth $860,000 after buying an additional 634 shares during the period. Finally, Mackenzie Financial Corp raised its position in DexCom by 26.4% in the first quarter. Mackenzie Financial Corp now owns 29,516 shares of the medical device company’s stock valued at $15,100,000 after purchasing an additional 6,160 shares during the period. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Stock Up 1.0 %

NASDAQ:DXCM traded up $1.33 during trading hours on Thursday, hitting $135.19. 701,939 shares of the stock traded hands, compared to its average volume of 2,964,936. The firm has a 50 day moving average price of $129.20 and a 200 day moving average price of $116.28. The company has a current ratio of 2.84, a quick ratio of 2.48 and a debt-to-equity ratio of 1.18. DexCom, Inc. has a fifty-two week low of $74.75 and a fifty-two week high of $142.00. The firm has a market cap of $52.12 billion, a price-to-earnings ratio of 102.18, a PEG ratio of 2.35 and a beta of 1.20.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, February 8th. The medical device company reported $0.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.43 by $0.07. DexCom had a net margin of 14.95% and a return on equity of 28.31%. The company had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $1.02 billion. During the same period in the previous year, the business earned $0.34 EPS. The company’s revenue was up 26.9% on a year-over-year basis. Equities research analysts anticipate that DexCom, Inc. will post 1.76 earnings per share for the current year.

Insider Buying and Selling at DexCom

In other news, CFO Jereme M. Sylvain sold 3,363 shares of the company’s stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $116.73, for a total value of $392,562.99. Following the transaction, the chief financial officer now directly owns 71,142 shares of the company’s stock, valued at $8,304,405.66. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, EVP Sadie Stern sold 20,321 shares of the company’s stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $133.61, for a total value of $2,715,088.81. Following the transaction, the executive vice president now directly owns 80,441 shares of the company’s stock, valued at $10,747,722.01. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Jereme M. Sylvain sold 3,363 shares of the company’s stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $116.73, for a total transaction of $392,562.99. Following the completion of the sale, the chief financial officer now owns 71,142 shares of the company’s stock, valued at $8,304,405.66. The disclosure for this sale can be found here. Insiders have sold a total of 189,375 shares of company stock valued at $25,530,859 in the last three months. 0.41% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

DXCM has been the topic of several research reports. Citigroup raised their price objective on DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a research report on Wednesday, April 3rd. StockNews.com upgraded DexCom from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. Raymond James raised their target price on DexCom from $147.00 to $151.00 and gave the company a “strong-buy” rating in a research note on Tuesday, January 23rd. Royal Bank of Canada assumed coverage on DexCom in a research note on Tuesday, March 12th. They set an “outperform” rating and a $165.00 target price for the company. Finally, UBS Group boosted their price objective on DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a report on Wednesday, April 10th. Two analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $141.40.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.